APNHY
Price
$6.37
Change
+$0.16 (+2.58%)
Updated
Aug 12 closing price
Capitalization
2.84B
ESALF
Price
$31.10
Change
+$0.10 (+0.32%)
Updated
Aug 15 closing price
Capitalization
8.89B
Interact to see
Advertisement

APNHY vs ESALF

Header iconAPNHY vs ESALF Comparison
Open Charts APNHY vs ESALFBanner chart's image
Aspen Pharmacare Holdings
Price$6.37
Change+$0.16 (+2.58%)
Volume$190
Capitalization2.84B
Eisai
Price$31.10
Change+$0.10 (+0.32%)
Volume$370
Capitalization8.89B
APNHY vs ESALF Comparison Chart in %
Loading...
APNHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APNHY vs. ESALF commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APNHY is a Hold and ESALF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (APNHY: $6.36 vs. ESALF: $31.10)
Brand notoriety: APNHY and ESALF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: APNHY: 4% vs. ESALF: 12%
Market capitalization -- APNHY: $2.84B vs. ESALF: $8.89B
APNHY [@Pharmaceuticals: Generic] is valued at $2.84B. ESALF’s [@Pharmaceuticals: Generic] market capitalization is $8.89B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APNHY’s FA Score shows that 1 FA rating(s) are green whileESALF’s FA Score has 2 green FA rating(s).

  • APNHY’s FA Score: 1 green, 4 red.
  • ESALF’s FA Score: 2 green, 3 red.
According to our system of comparison, ESALF is a better buy in the long-term than APNHY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APNHY’s TA Score shows that 3 TA indicator(s) are bullish while ESALF’s TA Score has 5 bullish TA indicator(s).

  • APNHY’s TA Score: 3 bullish, 6 bearish.
  • ESALF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ESALF is a better buy in the short-term than APNHY.

Price Growth

APNHY (@Pharmaceuticals: Generic) experienced а +2.84% price change this week, while ESALF (@Pharmaceuticals: Generic) price change was +3.67% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ESALF($8.89B) has a higher market cap than APNHY($2.84B). ESALF has higher P/E ratio than APNHY: ESALF (27.95) vs APNHY (11.05). ESALF YTD gains are higher at: 21.059 vs. APNHY (-22.942). ESALF has higher annual earnings (EBITDA): 104B vs. APNHY (8.02B). ESALF has more cash in the bank: 266B vs. APNHY (6.8B). APNHY has less debt than ESALF: APNHY (35.5B) vs ESALF (188B). ESALF has higher revenues than APNHY: ESALF (789B) vs APNHY (45.5B).
APNHYESALFAPNHY / ESALF
Capitalization2.84B8.89B32%
EBITDA8.02B104B8%
Gain YTD-22.94221.059-109%
P/E Ratio11.0527.9540%
Revenue45.5B789B6%
Total Cash6.8B266B3%
Total Debt35.5B188B19%
FUNDAMENTALS RATINGS
APNHY vs ESALF: Fundamental Ratings
APNHY
ESALF
OUTLOOK RATING
1..100
8933
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
10
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
996
PRICE GROWTH RATING
1..100
6447
P/E GROWTH RATING
1..100
9392
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APNHY's Valuation (10) in the null industry is in the same range as ESALF (10). This means that APNHY’s stock grew similarly to ESALF’s over the last 12 months.

APNHY's Profit vs Risk Rating (100) in the null industry is in the same range as ESALF (100). This means that APNHY’s stock grew similarly to ESALF’s over the last 12 months.

ESALF's SMR Rating (6) in the null industry is significantly better than the same rating for APNHY (99). This means that ESALF’s stock grew significantly faster than APNHY’s over the last 12 months.

ESALF's Price Growth Rating (47) in the null industry is in the same range as APNHY (64). This means that ESALF’s stock grew similarly to APNHY’s over the last 12 months.

ESALF's P/E Growth Rating (92) in the null industry is in the same range as APNHY (93). This means that ESALF’s stock grew similarly to APNHY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APNHYESALF
RSI
ODDS (%)
Bullish Trend 1 day ago
58%
Bearish Trend 1 day ago
33%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
62%
Momentum
ODDS (%)
Bearish Trend 1 day ago
58%
Bullish Trend 1 day ago
35%
MACD
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
39%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 1 day ago
37%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
44%
Advances
ODDS (%)
Bullish Trend 4 days ago
66%
Bullish Trend 15 days ago
38%
Declines
ODDS (%)
Bearish Trend 10 days ago
58%
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
68%
Aroon
ODDS (%)
Bearish Trend 1 day ago
59%
Bearish Trend 1 day ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
APNHY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ESALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ONLN57.680.18
+0.31%
ProShares Online Retail ETF
FIXP19.800.03
+0.15%
FolioBeyond Enhanced Fixed Inc Prm ETF
FPEI19.210.01
+0.05%
First Trust Instl Pref Secs and Inc ETF
IBHG22.43N/A
+0.02%
iShares® iBonds® 2027 Term HY & Inc ETF
PRAE33.11N/A
N/A
PlanRock Alternative Growth ETF

APNHY and

Correlation & Price change

A.I.dvisor tells us that APNHY and TRUFF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APNHY and TRUFF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APNHY
1D Price
Change %
APNHY100%
N/A
TRUFF - APNHY
21%
Poorly correlated
-6.81%
PRFX - APNHY
20%
Poorly correlated
-4.93%
ESALF - APNHY
20%
Poorly correlated
+0.32%
SDZNY - APNHY
20%
Poorly correlated
+1.21%
BIOVF - APNHY
19%
Poorly correlated
N/A
More

ESALF and

Correlation & Price change

A.I.dvisor tells us that ESALF and ESAIY have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESALF and ESAIY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESALF
1D Price
Change %
ESALF100%
+0.32%
ESAIY - ESALF
26%
Poorly correlated
+2.73%
DVAX - ESALF
23%
Poorly correlated
+1.60%
KHTRF - ESALF
22%
Poorly correlated
N/A
SHPH - ESALF
22%
Poorly correlated
-5.14%
BLMH - ESALF
21%
Poorly correlated
-5.98%
More